The Anticancer Effect of Chinese Medicine Formulation Olive Branch-1
Grant Data
Project Title
The Anticancer Effect of Chinese Medicine Formulation Olive Branch-1
Principal Investigator
Professor Che, Chi Ming
(Project Coordinator (PC))
Co-Investigator(s)
Dr Sy Lai King
(Co-Investigator)
Dr Wo Henry Lam Kee
(Co-Investigator)
Dr Lok Chun Nam
(Co-Investigator)
Dr Fung Eva Yi Man
(Co-Investigator)
Duration
21
Start Date
2018-03-05
Amount
367432
Conference Title
The Anticancer Effect of Chinese Medicine Formulation Olive Branch-1
Presentation Title
Keywords
Anticancer Effect, Chinese Medicine, Formulation, Olive Branch-1
Discipline
Biochemistry
Panel
Physical Sciences (P)
HKU Project Code
InP/055/18
Grant Type
Innovation and Technology Fund Internship Programme
Funding Year
2017
Status
Completed
Objectives
Olive Branch-1 (OB-1) is a formulation containing Chinese medicines clinically used for cancer treatment. It has been prescribed by physicians for more than 17 years notably effective for lung, colorectal and lymphatic cancers. The ultimate objective of R&D work of OB-1 is to register and commercialize OB-1 as a proprietary Chinese medicine (pCm) in Hong Kong and other countries for treating cancer. The anticancer effect of OB-1 will primarily be investigated by five major approaches: (a) establish chemical fingerprint and quality evaluation of OB-1 by UPLC-MS-QTOF for identification and quality control; (b) explore the possibility of streamlining the OB-1 formulation without affecting or even enhancing its efficacy; (c) investigate the in vivo effects of OB-1 in animal models; (d) use molecular biology, transcriptomic and proteomic techniques to study the mechanistic action of OB-1 and (e) study the immunomodulatory effects of OB-1. The deliverables brought by the proposed project will steer participating company to make strategic investment on R&D projects including the proposed one. The benefit brought by the project not only on promoting university's and company's technological level but also on giving innovative insights to other Chinese medicine formulations such as OB-2 and OB-3, which have been lined up to be developed.